Goldman Sachs Sticks with Sell on Novartis Despite Improved Earnings
Goldman Sachs has maintained its Sell rating on Novartis AG (NOVN) with a price target of CHF110.00, according to James Quigley from Goldman Sachs.
The company's shares closed yesterday at CHF119.96.
Quigley is ranked #11844 out of 12433 analysts by TipRanks.
Novartis AG reported a quarterly revenue of CHF14.16 billion and a net profit of CHF3.21 billion for the quarter ending June 30.
This compares to last year's revenue of CHF14.84 billion and net profit of CHF4.04 billion.